Alzheimer's disease biomarker assessment to be added to the Phase 1b/2a trial
TSX Exchange Symbol: RVX
CALGARY, April 28 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or "Company") (TSX:RVX) is pleased to provide a corporate update on activities as well as an interim progress report for Resverlogix's lead drug, RVX-208. Currently Resverlogix is conducting a human Phase 1b/2a clinical trial for the assessment of RVX-208, a new class of drugs, for the treatment of atherosclerosis. The primary endpoints for this trial are safety and tolerability. To date, Resverlogix would also like to announce that RVX-208 has demonstrated that it is safe, tolerable and has favorable pharmacokinetics. The study is a double blinded placebo trial, thus an interim analysis will not be released until after the completion date of July 2009. As a result of the recently announced financing, completion of the third arm of the Phase 1b/2a trial has recommenced. Resverlogix is also pleased to announce that it will be adding a new assessment of a biomarker for Alzheimer's disease to the third and final arm of this clinical trial.
"The unmet medical need of treating subjects with low levels of ApoA-I, "the HDL protein", is huge. RVX-208 has received a great deal of recognition based on current data. In parallel with advancing the clinical program for RVX-208 we have also made distinct progress in delineating the unique mechanism of action by which RVX-208 increases ApoA-I production," stated Donald J. McCaffrey, President and CEO of Resverlogix. "This data will in part be communicated by Dr. Norman Wong, MD and Chief Scientific Officer of Resverlogix at the upcoming American Heart Association (AHA) conference," added McCaffrey.
Resverlogix is also pleased to announce that it will host a live teleconference on Thursday, April 30, 2009 at 10:00 am MDT. The purpose of the teleconference is to provide a year-end upd
|SOURCE Resverlogix Corp.|
Copyright©2009 PR Newswire.
All rights reserved